X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
male (8) 8
oncology (7) 7
humans (6) 6
aged (5) 5
deoxycytidine - analogs & derivatives (5) 5
female (5) 5
middle aged (5) 5
pyrazoles - administration & dosage (5) 5
pyrimidines - administration & dosage (5) 5
activation (4) 4
adult (4) 4
animals (4) 4
dose-response relationship, drug (4) 4
kidney - metabolism (4) 4
neoplasms - drug therapy (4) 4
rats (4) 4
rats, sprague-dawley (4) 4
treatment outcome (4) 4
cells (3) 3
chemistry, medicinal (3) 3
chemistry, multidisciplinary (3) 3
chk1 (3) 3
deoxycytidine - pharmacokinetics (3) 3
disposition (3) 3
drug administration schedule (3) 3
efficacy (3) 3
in vitro techniques (3) 3
infusions, intravenous (3) 3
pharmacokinetics (3) 3
pharmacology & pharmacy (3) 3
therapy (3) 3
administration, oral (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antiviral agents - pharmacokinetics (2) 2
article (2) 2
carboplatin - administration & dosage (2) 2
checkpoint kinase 1 (2) 2
chemotherapy (2) 2
clearance (2) 2
cytarabine - administration & dosage (2) 2
deoxycytidine - administration & dosage (2) 2
disease-free survival (2) 2
drug resistance, neoplasm (2) 2
emtricitabine (2) 2
expression (2) 2
healthy-volunteers (2) 2
histones - metabolism (2) 2
isolated perfused kidney (2) 2
lamivudine (2) 2
maximum tolerated dose (2) 2
mk-1775 (2) 2
neoplasms - blood (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
pembrolizumab (2) 2
perfused rat-kidney (2) 2
perfusion (2) 2
phosphorylation (2) 2
prognosis (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinases - metabolism (2) 2
pyrazoles - adverse effects (2) 2
pyrimidines - adverse effects (2) 2
renal excretion (2) 2
replication (2) 2
sulfamethoxazole (2) 2
trimethoprim (2) 2
ucn-01 (2) 2
young adult (2) 2
1-beta-d-arabinofuranosylcytosine 5'-triphosphate (1) 1
3tc (1) 1
acute myelogenous leukemia (1) 1
acute myeloid-leukemia (1) 1
adenocarcinoma - drug therapy (1) 1
advanced bladder-carcinoma (1) 1
advanced melanoma (1) 1
advanced solid tumors (1) 1
advanced tumors (1) 1
aged, 80 and over (1) 1
analogs (1) 1
analysis (1) 1
analysis of variance (1) 1
anions (1) 1
anti-infective agents - pharmacology (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - blood (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - blood (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, immunological - administration & dosage (1) 1
antineoplastic agents, immunological - blood (1) 1
antineoplastic agents, immunological - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - pharmacokinetics (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antitumor-activity (1) 1
apoptosis (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 30, pp. 3409 - 3415
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 3063 - 3063
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 9, pp. 1060 - 1066
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2016, Volume 34, Issue 36, pp. 4371 - 4380
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. CT112 - CT112
Background: The anti-PD-1 monoclonal antibody pembrolizumab has demonstrated durable antitumor activity against several advanced malignancies and is generally... 
Journal Article
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, ISSN 0277-3732, 10/2019, Volume 42, Issue 10, pp. 802 - 809
Objective: The purpose of this systematic literature review (SLR) and meta-analysis was to compile the response of historic treatment options in first-line... 
duration of response | ADVANCED BLADDER-CARCINOMA | UNFIT PATIENTS | DOXORUBICIN | RENAL-FUNCTION | GEMCITABINE | CHEMOTHERAPY | clinical response | PHASE-II TRIAL | ONCOLOGY | bladder cancer | TRANSITIONAL-CELL CARCINOMA | overall survival | PACLITAXEL PLUS CARBOPLATIN | treatment naive | Neoadjuvant therapy | Treatment outcome | Drug therapy | Bladder cancer | Patient outcomes | Analysis
Journal Article
Journal for immunotherapy of cancer, ISSN 2051-1426, 08/2019, Volume 7, Issue 1, pp. 212 - 8
Pembrolizumab is a potent, humanized, monoclonal anti-programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in... 
Immunogenetics | Research | Gene expression | Apoptosis | Efficacy | Advanced tumors | Pembrolizumab | Treatment-emergent ADA | Safety | Immunogenicity
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2012, Volume 18, Issue 24, pp. 6723 - 6731
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2016, Volume 34, Issue 36, p. 4354
Purpose AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of chemopotentiation in p53-deficient tumors in preclinical models. In... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2016, Volume 34, Issue 36, p. 4371
Purpose AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. This phase I... 
Journal Article
01/2007, ISBN 0549281088
An isolated perfused rat kidney (IPK) model was utilized to characterize the renal excretion of Emtricitabine (FTC). The propose of this dissertation are as... 
Pharmaceuticals
Dissertation
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.